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Abstract
Background: Enhancer of zeste homolog 2 (EZH2) is a polycomb-group protein that is involved in stem cell
renewal and carcinogenesis. In breast cancer, increased EZH2 expression is associated with aggressiveness and
has been suggested to identify normal breast epithelium at increased risk of breast cancer development. However,
the association between EZH2 expression in benign breast tissue and breast cancer risk has not previously been
evaluated in a large prospective cohort.
Methods: We examined the association between EZH2 protein expression and subsequent breast cancer risk using
logistic regression in a nested case-control study of benign breast disease (BBD) and breast cancer within the
Nurses’ Health Studies. EZH2 immunohistochemical expression in normal breast epithelium and stroma was
evaluated by computational image analysis and its association with breast cancer risk was analyzed after adjusting
for matching factors between cases and controls, the concomitant BBD diagnosis, and the Ki67 proliferation index.
Results: Women with a breast biopsy in which more than 20% of normal epithelial cells expressed EZH2 had a
significantly increased risk of developing breast cancer (odds ratio (OR) 2.95, 95% confidence interval (CI) 1.11–7.84)
compared to women with less than 10% EZH2 epithelial expression. The risk of developing breast cancer increased
for each 5% increase in EZH2 expression (OR 1.22, 95% CI 1.02–1.46, p value 0.026). Additionally, women with high
EZH2 expression and low estrogen receptor (ER) expression had a 4-fold higher risk of breast cancer compared to
women with low EZH2 and low ER expression (OR 4.02, 95% CI 1.29–12.59).
Conclusions: These results provide further evidence that EZH2 expression in the normal breast epithelium is
independently associated with breast cancer risk and might be used to assist in risk stratification for women with
benign breast biopsies.
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Background
Prior studies have elucidated a variety of clinical, epidemio-
logic, radiologic and histopathologic features associated
with an increased risk of breast cancer. However, our
understanding of breast cancer risk factors and carcinogen-
esis in the normal breast is still rudimentary, limiting our
ability to predict breast cancer risk accurately. Currently,
germline mutations in high penetrance cancer predispos-
ition genes (i.e. BRCA1/2), family history, and mammo-
graphic density have major ability to predict breast cancer,
with other factors such as reproductive history playing a
smaller role in determining risk [1–3]. Among the breast
tissue-based predictors of future cancer risk, atypical hyper-
plasia (atypical ductal hyperplasia and atypical lobular
hyperplasia) is the strongest predictor and is associated with
a three to fivefold increase in the risk of breast cancer [4,
5]. Additionally, some tissue-specific biomarkers have been
associated with breast cancer risk in specific subsets of
women, such as insulin-like growth factor 1 receptor
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(IGF1R), and more recently, the combination of Ki67 and
estrogen receptor (ER) expression in a subset of women
[6–8]. However, additional biomarkers to stratify breast
cancer risk are needed.
Enhancer of zeste homolog 2 (EZH2) is a core protein
of the polycomb-repressive complex 2 (PRC2) that
controls dimethylation and trimethylation of Lys27 of
histone H3 (H3K27me3), a marker linked to transcrip-
tional silencing. Due to its role in regulating fundamen-
tal cellular processes, such as cell cycle regulation,
senescence and differentiation, EZH2 has been thought
to contribute to malignant transformation. However,
this view has been challenged and it has been suggested
that high EZH2 is a consequence rather than a cause of
cancer [9].
More relevant to this study, the expression and prog-
nostic significance of EZH2 has been extensively investi-
gated and in breast cancer it is now generally accepted
to be associated with a worse prognosis [10]. Association
between EZH2 expression and poor prognosis has also
been reported in ductal carcinoma in situ (DCIS) [11].
More recently, in an analysis of the epithelial-stromal
co-expression networks in breast cancer, our group has
also suggested that stromal expression of EZH2 is
strongly associated with breast cancer expression signa-
tures and EZH2 expression in the epithelium of ER-
negative invasive breast cancer (IBC) [12]. Also EZH2
has recently been found more frequently in the stroma
of malignant phyllodes tumors (PT) when compared to
normal breast tissue and borderline PT [13]. However,
studies addressing the clinical relevance of EZH2 expres-
sion in benign breast disease and normal breast tissue as
a biomarker of breast cancer risk have been limited by
small sample sizes [14, 15]. Therefore, we performed an
immunohistochemistry-based evaluation of EZH2 ex-
pression in normal breast tissue in women with biopsy-
confirmed benign breast disease (BBD) in the Nurses’
Health Studies and examined the association between
EZH2 expression and subsequent breast cancer risk.
Methods
Study subjects
This study is a nested case-control study of members of
the Nurses’ Health Study (NHS) and Nurses’ Health
Study II (NHS II) cohort with biopsy-confirmed BBD.
The NHS is an ongoing prospective cohort study that
began in 1976, when 121,700 female registered nurses
between the ages of 30 and 55 years completed a mailed
questionnaire. The NHS II consists of 116,609 female
registered nurses who were between the ages of 25 and
42 years when the study began in 1989. In both cohorts,
participants have been followed via biennial question-
naires that provide information on lifestyle factors (body
mass index (BMI), reproductive history, postmenopausal
hormone (PMH) use, and alcohol use) and incident
disease [3, 16]. The follow-up rate for each NHS/NHS II
two-year cycle has been greater than 90% of the original
cohorts.
Details on the BBD diagnosis reporting on the question-
naires have been previously described [2, 6]. Briefly, the
cases were women with biopsy-confirmed BBD who re-
ported a subsequent diagnosis of breast cancer following
their BBD diagnosis. Cases were diagnosed between 1976
and 1998 for the NHS and between 1989 and 1999 for the
NHS II. Self-reported breast cancers were confirmed by
review of medical records, and both invasive breast cancer
and carcinoma in situ were included in the study. To re-
duce potential reverse causation due to subclinical tissue
change, women were excluded if they had evidence of in
situ or invasive carcinoma at biopsy or reported a diagno-
sis of breast cancer within 6 months of their BBD biopsy.
There was a median 9 years between BBD biopsy and can-
cer diagnosis among the cases.
Eligible controls were women who completed the
questionnaire in the same year that the breast cancer
case was reported and had a previous diagnosis of
biopsy-confirmed BBD, but were free from breast can-
cer at the time of the case (index date). Using incidence
density sampling, up to four controls were selected for
each breast cancer case by age at index date, year of
BBD biopsy, and time since BBD biopsy. Due to consider-
able missing information on the laterality of the carcin-
oma in the cases, this information was not considered in
analysis. The study was approved by the Human
Subjects Research Committee of Brigham and Women’s
Hospital, Boston, Massachusetts. Completion of the
self-administered questionnaire was presumed to imply
informed consent.
Benign breast biopsy specimens and immunohistochemical
evaluation
Eligible cases and controls were contacted for permis-
sion to obtain their BBD pathology records and biopsy
specimens, and specimens were then obtained from
hospital pathology departments when possible (as de-
tailed in [2, 17, 18]). The ability to obtain biopsy blocks
did not significantly differ by case and control status.
Biopsy slides were independently reviewed by one of
three breast pathologists. The details of this nested
case-control study and the BBD assessment have been
described previously [2, 6, 17]. There were 463 cases
and 1853 controls, in whom the original slides had been
reviewed and were eligible for the block collection. Of
these, we successfully obtained BBD blocks from 177
cases and 719 controls. There were 388 participants
who were eligible for the tissue microarray (TMA) con-
struction by having one or more of the following types
of benign lesions: apocrine metaplasia, non-apocrine
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cysts, usual ductal hyperplasia, atypical ductal hyperpla-
sia (ADH), or atypical lobular hyperplasia (ALH). The
TMAs were constructed in the Dana Farber Harvard
Cancer Center Tissue Microarray Core Facility, Boston,
MA, USA, by obtaining 0.6-mm cores from the tar-
geted areas, which included lesions and up to three
cores for normal terminal ductal lobular units (TDLUs)
in each donor block and inserting them into the recipi-
ent TMA blocks. Three cores were obtained for 96% of
the targeted areas.
For each immunohistochemical (IHC) stain, a 5-μm
paraffin section was cut from each TMA block and im-
munostained for EZH2 (EZH2, 1:300, BD Biosciences,
San Diego, CA, USA) after appropriate processing. Im-
munostaining was performed in a single staining run on
a Leica Bond automated stainer (Leica Biosystems Inc,
Nu loch, Germany). Positive and negative controls
were included in all staining runs. Details on the antigen
retrieval conditions and quantification are provided in
Additional file 1. Details on ERα and Ki67 immunostain-
ing and quantification in this cohort have been described
elsewhere [6, 19]. As with previous studies using this co-
hort, the intensity of staining was not scored, as staining
intensity can be affected by both storage time and vari-
ability in processing [20]. Owing to our samples being
from across the USA over a large period, it was felt that
the staining intensity would not be a reliable metric to
analyze.
Image analysis and quantification
Immunostaining results of each core were interpreted
using an automated computational image analysis sys-
tem (Definiens Tissue Studio software V4.1, Munich,
Germany). EZH2 expression was recorded as the per-
centage of EZH2-expressing cells with nuclear expres-
sion as previously reported [14, 15]. Due to the
hypothesis that EZH2 expression has a different bio-
logical significance in the stromal and epithelial com-
partments, the analysis pipeline included an epithelial/
stromal classifier and results per compartment were also
recorded (Fig. 1a). Only cells of normal TDLU’s were
considered for the epithelial compartment analyses and
tissue cores were excluded if containing fewer than 10
cells. The EZH2 expression in the BBD lesion was not
recorded, as the capacity to target the BBD lesion in this
cohort has been sub-optimal [21].
In the cell/nuclear identification and stain evaluation
module, we defined an intensity and size threshold for
nucleus identification and introduced an intensity
threshold for nuclear stain positivity. Based on these
criteria, each cell was classified as either positive or
negative. The classification as a continuous scale of
positive EZH2 cells was reviewed by a pathologist (FB),
blinded to outcome. The image analysis results were
strongly correlated with a manual 2 and 3-tier scoring
system (as detailed in Additional file 1). For each woman,
we estimated the mean percentage of stain-positive cells
Fig. 1 Imaging analysis of the normal breast tissue in the tissue microarrays (TMAs). a The pipeline used in this analysis consisted of the three
basic stages: TMA core detection and identification matching the identification grid with the core location (upper panel); region of interest (ROI)
segmentation, machine-learning-based training and application of the epithelium/stroma classifier (middle panel); and cell and nuclei detection
and staining evaluation (bottom panel, left side). Using this pipeline, data were readily available for downstream analysis (bottom panel, right side -
a detailed version of this panel is available in Additional file 1: Figure S2). b Representative images of immunohistochemical (IHC) expression of
EZH2 in normal breast tissues. Scale bar 200 μm
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across the cores, by weighting each core by the total cell
count in each of the compartments analyzed (stroma and
epithelium).
Statistical analysis
We used unconditional logistic regression analysis to
describe the association between EZH2 expression and
breast cancer risk. The risk estimates were presented as
odds ratios (ORs) and their corresponding 95% confi-
dence intervals (95% CIs). In the logistic regression ana-
lysis, we modeled EZH2 expression as both continuous
and categorical variables (0–10%, 11–20%, >20%). Cutoff
points were set based on previous reports [14, 22] and
data distribution clustering based on finite normal
mixture modeling (more details in Additional file 1).
The logistic regression models adjusted for the study
matching-factors (age at cancer diagnosis/index date,
year of BBD biopsy, time since BBD biopsy), type of
BBD lesion, and proliferative activity (using the Ki67
index). No imputation methods were used for handling
missing information.
Potential confounding by other established breast cancer
risk factors was evaluated by examining their association
with EZH2 expression, though no additional covariates
were included in the final models. We performed a test
for trend by conducting the Wald test when including the
EZH2 expression category in the model as the continuous
variable. Interactions between EZH2 expression and ER
and Ki-67 expression were evaluated by dichotomizing the
expression about the median level among controls and
performing a likelihood ratio test for the product term.
Polytomous logistic regression models were utilized to
evaluate EZH2 expression as a predictor of subsequent
breast tumor ER expression (ER+ case vs. control, ER-
case vs. control).
Statistical significance in all the analyses was assessed
at the level of 0.05. The analyses were performed using
SAS software (version 9.2, SAS Institute, Cary, NC,
USA). All the analysis performed and reporting are com-
pliant with the Transparent reporting of a multivariable
prediction model for individual prognosis or diagnosis
(TRIPOD) statement [23].
Results
Expression patterns of EZH2 in benign breast tissue
The percentage of EZH2-positive epithelial cells in nor-
mal TDLUs ranged from 0 to 50.00% with a median of
5.88% and an interquartile range (IQR) of 1.89–12.46%.
In stroma, the percentage of EZH2-positive cells ranged
from 0 to 58.39% with a median of 5.86% and an IQR of
3.09–10.91%. The intraclass correlation coefficient (ICC)
across cores was 0.69 (95% CI 0.63–0.74) in the epithe-
lium and 0.64 (95% CI 0.58–0.70) in stroma, suggesting
moderately low heterogeneity in EZH2 expression across
the cores. Stromal and epithelial expression of EZH2 in
normal breast tissue were moderately correlated (Spear-
man r = 0.79, p < 0.001 (see Additional file 1: Figure
S3)) and the distribution of the EZH2 expression in
both the normal epithelium and stroma was similar
across participants independent of the concomitant
BBD diagnosis category (Additional file 1: Figure S4).
Additionally, epithelial expression of EZH2 in normal
breast tissue was weakly/moderately correlated with
Ki67 (Spearman r = 0.39, p < 0.001) and weakly corre-
lated with p53 (Spearman r = 0.21, p = 0.001) and AR
expression (Spearman r = 0.18, p = 0.004). There was no
correlation between EZH2 and ER or PR expression
(Additional file 1: Table S4).
The mean age at cancer diagnosis was 53.2 years in the
74 cases included in the analysis with most developing
cancer 5 to 10 years after the breast biopsy. Compared
with controls, cases did not display significant differences
in age-standardized characteristics (Additional file 1: Table
S2). Additionally, age-standardized characteristics of con-
trols at breast biopsy by EZH2 expression levels were also
identical (Table 1).
EZH2 expression patterns in normal TDLUs and
subsequent breast cancer risk
Next, we examined the association between the per-
centage of cells positive for EZH2 in the normal TDLU
epithelium and subsequent risk of breast cancer in the
NHS and NHS II cohorts. When evaluating breast can-
cer risk by 5% increase in EZH2 expression and adjust-
ing for matching factors between cases and controls,
there was a significant increase in risk associated with
EZH2 expression in epithelium (OR = 1.17, 95% CI =
1.03–1.34, p value = 0.021) (Table 2). Results were simi-
lar after additional adjustment for BBD subtype and
proliferative activity as determined by Ki67 (OR = 1.22,
95% CI = 1.02–1.46, p value = 0.026). EZH2 expression
in stromal cells in normal breast tissue was not signifi-
cantly associated with subsequent breast cancer risk.
To compare with previous studies and facilitate clinical
translation of the results and estimation of EZH2
expression by a trained pathologist, we also tested
the association with categories of EZH2 expression
(Table 2). When using this scale, normal breast epithelium
with more than 20% expression of EZH2 expression was
associated with a 2.44-fold increased risk of breast cancer
(OR = 2.44, 95% CI = 1.15–5.17), which was even higher
when also adjusting for the BBD lesion present and for pro-
liferative activity (OR = 2.95, 95% CI = 1.11–7.84) (Table 2).
As the cases represented patients who developed
both invasive and in-situ carcinoma, we next con-
ducted sensitivity analysis including only the 62 inva-
sive breast cancer cases and found the results to be
robust when applying this restriction. In these women,
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>20% epithelial expression of EZH2 was associated with a
3.15-fold increase in breast cancer risk (OR = 3.15, 95% CI
1.39–7.14), relative to women with <10% expression of
EZH2. There was also a 1.22-fold increased risk of breast
cancer per 5% increase in epithelial EZH2 expression (OR
= 1.22, 95% CI 1.06–1.41).
Subsequent breast cancer risk and cross-classification
with ER and Ki67 expression
Due to the recently reported association between prolif-
erative activity in breast epithelium and breast cancer
risk [7, 8], we next cross-classified EZH2 with Ki67 and
ER expression to evaluate the potential effect of Ki67
and ER expression on the association of epithelial
EZH2 expression and subsequent breast cancer risk
(Table 3). For cross-classification, EZH2, ER and Ki67
expression were dichotomized at median expression.
EZH2 expression displayed a significant interaction
with ER expression (p = 0.017). Individuals with high
epithelial EZH2 and lower ER expression had a fourfold
increased risk of breast cancer development (OR = 4.02,
Table 1 Age-standardized characteristics of the controls at
breast biopsy by EZH2 expression category
















Year of BBD biopsy
Before 1980, % 42 33 46
1980–1989, % 44 53 43
After 1989, % 14 14 11
Time from biopsy to diagnosis/index date
0.5–4.9 years, % 48 50 45
5.0–9.9 years, % 25 23 18
10.0–14.9 years, % 19 20 34
15.0+ years, % 9 7 4
BBD category
Non-proliferative, % 32 28 29
Proliferative without atypia, % 53 61 66
Atypical hyperplasia, % 15 12 5
Age at first birth
Nulliparous, % 6 2 0
<25 years, % 57 42 71
25–29 years, % 30 42 13
30+ years, % 6 11 5
Missing, % 2 3 11
Duration of breastfeeding (months)b
0 months, % 37 37 22
0–3 months, % 20 19 50
4–11 months, % 20 26 7
12+ months, % 21 15 18
Missing, % 2 4 2
Age at menarche (years)
< 12, % 24 19 20
12, % 26 19 32
13, % 26 41 32
14+, % 23 21 16
Menopausal status/age at menopause (years)
Premenopausal, % 42 43 48
< 50, % 29 30 36
50+, % 24 19 16
Missing, % 5 9 0
Postmenopausal hormone therapy use
Never, % 26 24 33
Ever, % 30 25 16
Premenopausal, % 43 49 51
Table 1 Age-standardized characteristics of the controls at
breast biopsy by EZH2 expression category (Continued)
Missing, % 1 2 0
Oral contraceptive use
Never, % 51 50 34
Ever, % 46 50 66
Missing, % 3 0 0
BMI (kg/m2)
< 25.0, % 61 68 71
25.0–29.9, % 26 14 26
30.0+, % 13 17 4
Weight change since age 18 years
Gain <2 kg, % 17 13 16
Gain 2–10 kg, % 34 39 46
Gain 10+ kg, % 39 44 32
Missing, % 10 3 5
Alcohol consumption (g/week)
None, % 37 36 36
0.1–4.9, % 32 32 42
5.0–14.9, % 23 15 11
15.0+, % 9 17 11
Family history of breast cancer
No family history, % 81 91 82
Family history, % 19 9 18
Values are means (SD) or percentages and are standardized to the age
distribution of the study population. Values of polytomous variables may not
sum to 100% due to rounding. aValue is not age-adjusted. bFor parous women
only. EZH2 enhancer of zeste homolog 2, TDLU normal terminal ductal lobular
units, BMI body mass index, BBD benign breast disease
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95% CI = 1.29 –12.59) compared with those who had low
EZH2 and ER expression. There was no statistical associ-
ation with co-expression of Ki67. However, the association
between risk and EZH2 expression in cases with Ki67
below the median was close to statistical significance (OR
= 2.62, 95% CI = 0.98 –7.01). The increased risk of EZH2
expression in cases with low ER expression and potentially
in cases with low Ki67 expression suggests that the effect
of EZH2 in breast carcinogenesis could be dependent on
the biologic activity of estrogens and more pronounced in
low proliferative states).
Differential ER-positive and ER-negative breast cancer risk
by EZH2 expression
EZH2 overexpression had been associated with aggressive
ER-negative IBC [22, 24] and we previously identified it
as one of the most connected genes in ER-negative
IBC [12]. Therefore, we tested the association be-
tween EZH2 expression and the risk of a specific
subtype of IBC. Despite the association between
EZH2 expression and ER-negative breast cancer, we
found no association between EZH2 expression and
risk of ER-negative IBC. However, EZH2 expression
in >20% of epithelial cells in normal breast tisse was
associated with a 3.10-fold increased risk of ER-
positive breast cancer (OR = 3.10, 95% CI = 1.24–
7.72), when adjusting for matching factors and BBD
category. Although suggesting differential biological
significance of EZH2 in normal breast and in estab-
lished IBC, these results should be interpreted with
caution due to the small sample size in this particu-
lar analysis.
Table 2 Odds ratio (95% CI) of developing breast cancer by category and 5% increase of EZH2 expression in epithelium or stroma
in normal breast tissue
EZH2 expression By category Per 5% increase
≤10% 11–20% >20% P value for trend P value
Epithelium
Number of subjects (cases/controls) 48/184 10/55 16/30 74/269
Model 1a Ref. 0.70 (0.32–1.54) 2.44 (1.15–5.17) 0.078 1.17 (1.03–1.34) 0.021
Model 2b Ref. 0.73 (0.3–1.63) 2.67 (1.24–5.76) 0.053 1.20 (1.04– 1.38) 0.010
Model 3c Ref. 0.79 (0.32–1.96) 2.95 (1.1–7.84) 0.092 1.22 (1.02–1.46) 0.026
Stroma
Number of subjects (cases/controls) 53/208 20/72 5/12 78/292
Model 1a Ref. 1.06 (0.58–1.96) 1.94 (0.62–6.07) 0.379 1.12 (0.93–1.35) 0.230
Model 2b Ref. 1.20 (0.6 –2.23) 2.13 (0.67–6.80) 0.227 1.15 (0.95–1.39) 0.147
Model 3c Ref. 1.32 (0.61–2.85) 2.45 (0.64–9.37) 0.189 1.18 (0.94–1.49) 0.157
Matching factors: age at cancer diagnosis/index date, year of biopsy and, time between benign breast disease (BBD) biopsy and cancer diagnosis/index date.
aModel 1: adjusting for matching factors. bModel 2: adjusting for matching factors and BBD category. cModel 3: adjusting for Model 2 + Ki67. EZH2 enhancer of
zeste homolog 2, Ref. reference
Table 3 Odds ratios (95% confidence interval) of developing subsequent breast cancer according to cross-classified groups of EZH2
and ER, and Ki67 in normal breast tissue




Low EZH2/low ER 10 38 1.0 (Ref) 1.0 (Ref.)
Low EZH2/high ER 7 35 0.97 (0.32–2.94) 1.07 (0.35–3.31)
High EZH2/low ER 12 15 3.90 (1.27–11.99) 4.02 (1.29–12.59)
High EZH2/high ER 1 18 0.24 (0.03–2.09) 0.19 (0.02–1.70)
P value for interaction 0.031 0.017
Low EZH2/low Ki67 13 65 1.0 (Ref.) 1.0 (Ref.)
Low EZH2/high Ki67 7 29 1.49 (0.51–4.34) 1.56 (0.53–4.59)
High EZH2/low Ki67 12 31 2.62 (0.98–7.01) 2.40 (0.88–6.51)
High EZH2/high Ki67 22 68 1.67 (0.73–3.83) 1.78 (0.77–4.14)
P value for interaction 0.235 0.306
Matching factors: age at cancer diagnosis/index date, year of biopsy and, time between benign breast disease (BBD) biopsy and cancer diagnosis/index date.
Enhancer of zeste homolog 2 (EZH2), estrogen receptor (ER) and Ki67 expression categorized by median expression percentage. Only EZH2 epithelial expression
was considered for cross-classification. aModel 1: adjusting for matching factors, bModel 2: adjusting for matching factors and BBD category. Ref. reference
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Discussion
This is the first study, to our knowledge, to directly
examine the independent association between EZH2
expression in the normal breast and risk of breast can-
cer, in a large prospective study. We found that EZH2
expression in normal breast epithelium was associated
with breast cancer risk, particularly when >20% of the
epithelial cells expressed EZH2. Importantly, this asso-
ciation was independent of the two most important
tissue-specific risk factors in this population, the con-
comitant BBD lesion present and the proliferative activ-
ity as determined by Ki67 expression.
On its own, EZH2 expression in >20% of the normal
breast epithelial cells was associated with a threefold
increased risk of breast cancer, and a fourfold increased
risk if there is concomitant low ER expression. When
compared to other traditional risk factors, the magnitude
of the increased risk associated with higher EZH2 ex-
pression is in between the increased risk associated with
atypical hyperplasia and proliferative disease without
atypia, and is well above that associated with a positive
family history [5, 25]. Thus, we consider the level of risk
associated with high expression of EZH2 clinically sig-
nificant, especially if we consider the lack of biomarkers
of risk available for this group of patients.
Two prior studies have analyzed EZH2 expression in
normal breast and BBD lesions with the goal of estab-
lishing EZH2 as a potential marker of breast cancer risk
[14, 15]. Ding et al., reported similar prevalence of EZH2
expression according to the pathological diagnosis and
outcome (tumor development) to ours, and Kunju et al.,
reported an impressive area under the receiver operator
curve (AUC) of 0.88 for the ability of EZH2 to predict
breast cancer. However, both studies presented import-
ant limitations for translation to the clinical setting with
regard to design, small total sample size (12 and 59 sub-
jects, respectively) and a shorter follow-up time between
the biopsy and the development of cancer (6.7 years) in
the case group of the larger study [15].
In our secondary analysis, we found that the expres-
sion of ER appeared to modulate the effect of EZH2 on
breast cancer risk. When performing cross-classification
of samples using EZH2 and ER expression, women with
ER expression below the median in normal epithelium
and concomitant EZH2 expression above the median
displayed even higher risk of breast cancer than if only
using EZH2 for classification. A similar pattern of
effect modification of a risk biomarker and ER ex-
pression has also been recently reported. While Ki67
expression in normal breast epithelium was associated
with breast cancer risk, when cross-classification with
ER was performed, high Ki67 expression was no lon-
ger predictive of risk when high ER expression was
also detected [7].
Despite the similar pattern of association between risk
of breast cancer and effect modification with ER, in our
study there was only weak correlation between Ki67 and
EZH2, and no significant change in the magnitude of the
association between EZH2 and breast cancer risk when
including Ki67 expression as a covariate in the model.
While we cannot totally exclude the possibility that the
ability of EZH2 expression to predict breast cancer is
linked to cell proliferation, we favor the previously sug-
gested hypothesis that its role as a predictor of breast
cancer may depend on its effect on stem cell survival
and alteration of DNA repair pathways [24, 26–30].
We acknowledge a number of limitations in this study.
First, as we used TMAs, our expression data may not be
representative of the whole biopsy slide or breast, due to
sampling variability. Despite a very good intraclass correl-
ation coefficient for detection of EZH2 across biopsy cores,
and thus low heterogeneity in this sample, we tried to re-
duce this potential problem of variability by including all
patients with at least three TMA cores. Given the limited
sample size, we had limited power to estimate the effect
sizes, thus some of the results should be interpreted cau-
tiously, in particular the analyses using cross-classification
and the differential ER status of the different tumors. As in
previous studies using this cohort, women were excluded if
they did not provide biopsy specimens, did not have normal
TDLUs, or if there were insufficient numbers of cells in the
biopsy tissue blocks. However, our ability to obtain biopsy
blocks did not significantly differ by breast cancer case and
control status or by established breast cancer risk factors.
Finally, the generalizability of the result could be limited
to the population with concomitant BBD diagnosis in a
breast biopsy, as normal breast tissue adjacent to a BBD
may be different from that in women without BBD [31].
However, despite the limitations the prospective nature of
this cohort with significant follow-up time and the
reproducible methods used for biomarker quantification,
make this study uniquely suited to examine the associ-
ation between EZH2 expression in normal breast epithe-
lium and subsequent risk of breast cancer.
Conclusions
In conclusion, the currently available evidence suggests
EZH2 expression in the normal breast can be used as a
biomarker of breast cancer risk. In conjunction with
previously reported breast cancer risk biomarkers by
our group of investigators, such as IGF1R and Ki67,
these results reinforce a new paradigm of predicting
breast cancer risk by incorporating molecular markers
[6, 7]. Incorporation of these markers could help strat-
ify women into different risk groups and be the basis of
tailored screening strategies, and therefore have a major
impact in the care of the millions of women who
undergo breast biopsies each year.
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